Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG

Exclusion Criteria

• •1. Epilepsy and currently on medication.
• •2. Concomitant use of medicinal products with a known potential to cause QTc prolongation.
• •3. Patients with long QT syndromes.
• •4. History of thymectomy within 12 months before Screening.
• •5. An electrocardiogram (ECG) within 6 months before starting treatment that shows clinically significant abnormalities, in the opinion of the Investigator.
• •6. Breastfeeding or pregnant at Screening or planning to become pregnant at any time during the study.
• •7. Patients receiving immunomodulatory treatment (e.g. plasma exchange \[PE\], therapeutic plasma exchange \[TPE\], intravenous immunoglobulin G \[IVIG\]) should not have any treatment in the previous 4 weeks prior to Randomization or at any time during the study.
• •8. Use of rituximab or other similar biologic medications for immunomodulation within 6 months prior to Screening.
• •9. Treatment with an investigational drug (other than amifampridine) or device within 30 days before Screening or while participating in this study.
• •10. Any medical condition that, in the opinion of the Investigator, might interfere with the patient's participation in the study, poses an added risk for the patient, or confound the assessment of the patient.
• •11. History of drug allergy to any pyridine-containing substances or any amifampridine excipient(s).